NX Development Corp (“NXDC”) is pleased to announce that it is once again distributing Gleolan® (aminolevulinic acid HCl) in the United States, supporting neurosurgeons in fluorescence-guided surgery for patients with high-grade glioma.
Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Administered orally two to four hours before resection, Gleolan causes tumor cells to fluoresce under a blue-light-enabled surgical microscope, helping distinguish malignant from normal tissue in real time.
Today, more than 400 hospitals nationwide use Gleolan, and that number continues to grow as more institutions adopt fluorescence-guided technology. NXDC partners closely with hospitals and neurosurgeons to ensure smooth onboarding, training, and compliance with hospital pharmacy standards.
“Our focus is always on supporting clinicians who dedicate their work to patients living with gliomas,” said Salvatore DeSena, MD, Chief Executive Officer of NX Development Corp. “We’re proud to continue expanding the reach of Gleolan and the innovation it brings to surgical visualization.”
NXDC also collaborates with the neurosurgical community through training programs, professional conferences, and ongoing educational support. The company’s mission is to ensure that healthcare teams have the tools and knowledge they need to perform fluorescence-guided surgery safely and effectively.
About NX Development Corp
NX Development Corp (NXDC) is a Lexington, Kentucky–based pharmaceutical company dedicated to advancing optical imaging solutions that enhance surgical precision. As the exclusive U.S. distributor of Gleolan (aminolevulinic acid HCl), NXDC works in close collaboration with hospitals, neurosurgeons, and pharmacists to support the safe and effective use of fluorescence-guided surgery.
NXDC is committed to providing personalized customer support, streamlined ordering processes, and hands-on training resources for surgical teams across the country. Through its partnerships with healthcare professionals, NXDC continues to drive innovation that helps improve outcomes for patients with gliomas.
For more information, visit www.gleolan.com or email [email protected].
Important Safety Information
Contraindications
Do not use Gleolan in patients with hypersensitivity to aminolevulinic acid (ALA) or porphyrins acute or chronic types of porphyria. Please see Full Prescribing Information & Important Safety Information
